Bayer Animal Health reported today that it has acquired a chewable application from Piedmont Pharmaceuticals of Greensboro, N.C.
The technology, which is close to market approval, is designed to make it easier to administer different active ingredients to animals.
Part of the agreement gives Bayer access to two products in late-stage development.
Terms of the agreement were not disclosed.
“With this platform technology and access to two products already in advanced development, we will complement our internal R&D efforts and expand our portfolio of offerings to veterinarians and to our customers,” said Dr. Jean-Luc Lowinski, head of Germany-based Bayer Animal Health. “This technology will enable us to provide a whole new range of products to improve companion animal health and well being.”
The products are expected to roll out in a few years.
Piedmont participated in the Kansas City Animal Health Corridor Investment forum this year to showcase its soft chew technology. Read more about the conference here.